EBITDA Margin % is calculated as EBITDA divided by its Revenue. AnaptysBio's EBITDA for the
three
months ended in Mar. 2026 was $-31.4 Mil. AnaptysBio's Revenue for the
three
months ended in Mar. 2026 was $25.6 Mil. Therefore, AnaptysBio's EBITDA margin for the quarter that ended in Mar. 2026 was -122.77%.
AnaptysBio (NAS:ANAB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
AnaptysBio EBITDA Margin % Related Terms
AnaptysBio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for AnaptysBio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANAB vs VIR, GHRS, INVA: EBITDA Margin % Comparison
For the Biotechnology subindustry, AnaptysBio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AnaptysBio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AnaptysBio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where AnaptysBio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnaptysBio (ANAB) has a EBITDA Margin % of -122.77% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AnaptysBio and its competitors. According to the industry distribution chart, AnaptysBio ranks #128 out of 945 companies in the Biotechnology industry, placing it in the top 13.5%.
Is AnaptysBio's EBITDA Margin % too high?
AnaptysBio's current EBITDA Margin % is -122.77%. Based on the distribution chart, AnaptysBio ranks #128 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AnaptysBio has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's EBITDA Margin % compare to VIR and GHRS?
According to the Biotechnology industry distribution chart, AnaptysBio ranks #128 out of 945 companies for EBITDA Margin %. This places AnaptysBio in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AnaptysBio and its competitors. AnaptysBio's current EBITDA Margin % is -122.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
Based on GuruFocus' analysis, AnaptysBio (ANAB) is currently considered Fairly Valued. The stock's GF Value™ is $61.87, compared to a current price of $59.70 — trading 3.5% below its estimated fair value. The current EBITDA Margin % is -122.77%. AnaptysBio's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AnaptysBio (ANAB), the current EBITDA Margin % is -122.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AnaptysBio (ANAB) Overvalued in 2026?
Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued.
The current stock price of $59.70 is trading 3.5% below its estimated GF Value™ of $61.87.
GuruFocus considers AnaptysBio to be Fairly Valued.
Key valuation signals for ANAB:
EBITDA Margin %: -122.77%
GF Value™: $61.87 vs. price of $59.70 (3.5% below fair value)
No single metric tells the full story. See the ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
67GF Score
Get the complete analysis for ANAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANAB has been successfully added to your 
